A phase I safety and pharmacokinetic study of SU011248 [sunitinib] in combination with docetaxel in patients with advanced solid tumors
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2008
At a glance
- Drugs Docetaxel; Sunitinib
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 11 Jul 2008 Status changed from initiated to completed as reported by ClinicalTrials.gov.
- 15 Aug 2006 New trial record.